Brought to you by 
Arrowhead Pharmaceuticals nets $43.2mm through private placement
12 Aug 2016
Executive Summary
Arrowhead Pharmaceuticals Inc. netted $43.2mm through the private sale of 7.6mm shares at $5.90 (market average). Buyers included OrbiMed, RA Capital Management, Perceptive Advisors, RTW Investments, and other institutional investors. The company is developing compounds that trigger RNA interference and induce knockdown of disease-causing genes.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arrowhead Pharmaceuticals nets $43.2mm through private placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice